Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Deep Rectus Sheath Block for Laparoscopic Cholecystectomy

NCT06976320 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-09-09
Last updated
2025-09-22

Condition(s) studied

Cholecystectomy, LaparoscopicAnesthesiaPostoperative Pain

Investigational drug(s) / intervention(s)

Intravenous morphine patient control analgesiaIntravenous patient control analgesiaDeep rectus sheath block

Intravenous morphine patient control analgesia: 24-hour morphine consumption will be recorded

Intravenous patient control analgesia: 24-hour morphine consumption will be recorded

Deep rectus sheath block: Deep rectus sheath block will be administered at the end of the surgery.

Study summary

Postoperative pain after laparoscopic cholecystectomy can be considerable. Regional techniques such as erector spinae plane (ESP) block or transversus abdominis plane (TAP) block may be suitable for patients at increased risk of postoperative pain. The deep rectus sheath block is a novel block which is a modified version of the conventional rectus sheath block. It was reported in a few case reports that, it may be used for postoperative analgesia in patients undergoing laparoscopic cholecystectomy. The aim of this study is to investigate the postoperative analgesic efficacy of deep rectus sheath block in patients undergoing laparoscopic cholecystectomy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 80 years * Patients with American Society of Anesthesiology (ASA) physical status I-II * Patients scheduled for a laparoscopic cholecystectomy Exclusion Criteria: * Allergy to local anesthetics * Coagulopathy * Skin infection at the deep rectus sheath block area * Advanced hepatic or renal failure * Chronic pain syndromes * Alcohol or drug abuse * Severe pulmonary and/or cardiovascular disease * Psychiatric disorders

Primary outcome measure(s)

  • Morphine consumption — Postoperative 24 hours
    The amount of morphine required by the patient and given by the device will be recorded for the first 24 hours.

Trial sites (1)

FacilityCityRegionStatus
Istinye University Hospital Istanbul Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06976320 on ClinicalTrials.gov ↗ ← All trials in Turkey